NCT01030536 - Safety Study of CAT-8015 to Treat Advanced B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (NHL or CLL) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 15, 2010

Primary Completion Date

March 4, 2013

Study Completion Date

March 4, 2013

Conditions

Non-Hodgkin LymphomaChronic Lymphocytic Leukemia

Interventions

DRUG

CAT-8015 20 mcg/kg

Participants will receive 20 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.

DRUG

CAT-8015 30 mcg/kg

Participants will receive 30 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.

DRUG

CAT-8015 40 mcg/kg

Participants will receive 40 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.

DRUG

CAT-8015 50 mcg/kg

Participants will receive 50 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.

DRUG

CAT-8015 60 mcg/kg

Participants will receive 60 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.

Trial Locations (8)

20892

Research Site, Bethesda

29424

Research Site, Charleston

37203

Research Site, Nashville

46202

Research Site, Indianapolis

76508

Research Site, Temple

89169

Research Site, Las Vegas

Unknown

Research Site, Los Angeles

93-510

Research Site, Lodz